Avidity Biosciences

News

Novartis makes $12bn wager on RNA drugs with Avidity buy

Novartis is poised to make one of its largest takeover deals in its history after agreeing to buy RNA specialist Avidity Biosciences for $12bn.

News

Rumour mill says Novartis may want to buy Avidity

Novartis has made an offer to acquire RNA therapeutic specialist Avidity Biosciences, according to an unconfirmed report.

News

Buoyed by muscular dystrophy data, Avidity raises $345m

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an imp

News

RNA therapy firm Avidity files $400m placement

Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine

Novartis makes $12bn wager on RNA drugs with Avidity buy

Rumour mill says Novartis may want to buy Avidity

Buoyed by muscular dystrophy data, Avidity raises $345m

RNA therapy firm Avidity files $400m placement

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Avidity Biosciences

Editor's Picks